ArticleBMC infectious diseases2025
The prevalence of Mycoplasma pneumoniae and study of co-infection with COVID-19 from a laboratory perspective, before and after the relaxation of COVID-19 control measures.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveDescribe the prevalence of Mycoplasma pneumoniae (MP) in 2023, and investigate the influence of the relaxaion of COVID-19 pandemic control measures on MP prevalence. Analyze the positivity rates of MP in three distinct testing panels, assess clinical preferences for selecting these packages. Describe the co-infection status of MP with other respiratory pathogens, along with the laboratory characteristics of MP co-infection with COVID-19. Analyse the disparities in data between co-infected patients, healthy controls, and MP-only positive patients in terms of laboratory results, and speculate on its potential clinical implications. METHOD AND
resultsWe retrospectively collected and analyzed MP epidemiological and clinical data from 2022-2023 using three MP-related tests. The results showed that a total of 37,017 MP-related tests were conducted, with an overall positivity rate of 2.03%. Among the positive cases, 83.36% were aged 0-15 years. In 2023, there were 628 tests for MP and Chlamydia pneumoniae (CP) Nucleic Acid Test, with a positivity rate of 19.11%, surpassing the 347 cases in 2022, which had a positivity rate of 5.76%. Influenza A virus was the most commonly co-infected respiratory pathogen with MP. The laboratory results of the control, single-infection, and co-infection groups showed that in the complete blood count (CBC), COVID-19 may have altered the immune process of MP. The main reason for the abnormal biochemical results in both single and double-positive groups was insufficient nutrition, leading to reduced synthesis. The urinalysis results indicated that the double-positive group had higher renal pressure than the single-positive group.
conclusionMP entered the epidemic period in July following the relaxation of COVID-19 pandemic control measures. Additionally, COVID-19 may have altered the immune process of MP, impacting certain liver, heart, and kidney functions, as indicated by the laboratory results. Therefore, this study provides significant reference data for the clinical diagnosis and treatment of MP infections and co-infections with COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.